Waltham, Mass., July 03, 2025 (Globe Newswire)-Spyre Therapeutics, Inc. (Nasdaq: Syre) (the “Company” or “Spyre”), A Clinical-Stage Biotechnology Company Utilizing Best-In-Class Antibody Engineering, Dose Optimization to Target Improved Efficacy and Convenience in the Treatment of IBD and other Immune-Mediated The diseases today announced that the independent remuneration committee of Spyre of the Board Framework of the Spyre Therapeutics, Inc. 2018 Aquity incentive planning, as estimated (“2018 plan”). The stock options were approved on July 1, 2025 and were essential for the acceptance of employment by each employee at Spyre according to the Nasdaq listing rule 5635 (4).
The stock options were granted with a term of 10 years and an exercise price of $ 15.49, whereby the final course per share was reported on July 1, 2025. (1/48.) The shares that are subject to the respective options must always be carried out monthly monthly and continuously serve with Spyre by the applicable exercise dates. The stock options are subject to the conditions of the 2018 plan.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company in a clinical stage that is to be generated on an inflammatory bowel disease of the next generation (IBD) and other products for immune -mediated diseases by combining the first -class antibody technology, dose optimization and rational therapeutic combinations. The Spyre pipeline includes the extended semi-value half-value antibodies that aim to α4β7, TL1A and IL-23. For more information, see the Spyre website at www.spyre.com.
For investors:
Eric Mcintyre
VP for financial and investor relationships
Spyre therapeutics
[email protected]